Lung Therapeutics
Latest round
- Series C
Last raised
- Oct 2019
Total raised
- $53M
Investors
- 2
About Lung Therapeutics
Lung Therapeutics, Inc.Founded in 2012 and headquartered in Austin, US, Lung Therapeutics, Inc. specializes in developing therapies for fibrotic diseases.07 mn.Lung Therapeutics specializes in innovative therapies aimed at treating fibrosis, with a focus on multi-pathway approaches that address both anti-fibrotic and regenerative needs. The company's flagship product, LTI-03, is a groundbreaking therapy designed specifically for patients with Idiopathic Pulmonary Fibrosis (IPF). This dual-mechanism treatment works to improve lung function, reduce scarring, and promote homeostasis, thereby enhancing the overall quality of life for patients suffering from this debilitating condition. Lung Therapeutics targets various geographical markets, including North America and Europe, where there is a significant prevalence of fibrotic diseases and a need for advanced treatment options.Lung Therapeutics generates revenue through various channels, primarily focusing on partnerships with healthcare providers and institutions that utilize their therapies in clinical settings. Revenue is derived from the sale of their proprietary treatments, such as LTI-03, which are integrated into medical care for patients with IPF. The structure of these transactions typically involves direct sales to hospitals and clinics, where healthcare professionals administer the therapies to patients. The company may also engage in research partnerships with pharmaceutical companies, enhancing revenue through collaborative projects aimed at advancing fibrosis treatment solutions.Lung Therapeutics is focused on expanding its product offerings and geographic reach. The company plans to launch new therapies and enhance its existing product line by continuing to innovate in the fibrosis treatment space.07 mn, Lung Therapeutics will utilize these funds to support the development of upcoming products and expand its presence in North America and Europe. This strategic expansion aims to address the growing demand for effective therapies in markets where fibrotic diseases are prevalent.
Who invested in Lung Therapeutics
2 investors across 5 rounds
See all investors in Lung Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lung Therapeutics
Who invested in Lung Therapeutics?
Lung Therapeutics has 2 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lung Therapeutics raised?
Lung Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Lung Therapeutics last raise money?
Lung Therapeutics's most recent round on record is a Series C, in Oct 2019.
What does Lung Therapeutics do?
Lung Therapeutics is a pharmaceuticals company.
Where is Lung Therapeutics headquartered?
Lung Therapeutics is headquartered in Austin, US.
Which VCs invest in companies like Lung Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Lung Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Lung Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.